EGFR and neoplasm: Another study revealed that IACS-13909, a potent and specific allosteric inhibitor of SHP2, effectively inhibited tumor cell proliferation in vitro and caused regression of tumors in vivo in NSCLC models that exhibited resistance to osimertinib due to EGFR mutations (84).